[1]
Engels FK, Mathot RA, Verweij J. Alternative drug formulations of docetaxel: A review. Anticancer Drugs 2007; 18(2): 95-103.
[2]
Wang L, Liu Z, Liu D, Liu C, Juan Z, Zhang N. Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): Preparation, pharmacokinetics, tissue distribution and antitumor activity. Int J Pharm 2011; 413(1-2): 194-201.
[3]
Liu Q, Li R, Zhu Z, et al. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles. Int J Pharm 2012; 430(1-2): 350-8.
[4]
Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada - Clinical Trials Group. J Clin Oncol 1996; 14(2): 422-8.
[5]
Piccart MJ, Gore M, Ten Bokkel Huinink W, et al. Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995; 87(9): 676-81.
[6]
Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16(1): 187-96.
[7]
Ardavanis A, Tryfonopoulos D, Yiotis I, et al. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs 2004; 15(6): 581-5.
[8]
Palepu NR, Bulusu BT. Solubilized formulation of docetaxel without
tween 80. US Patent 20080319048A1, 2008
[9]
Shelley M, Harrison C, Coles B, et al. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 2006; 18(4): CD005247.
[10]
Van Poppel H. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer. Can J Urol 2005; 12: 81-5.
[11]
Baker J, Ajani J, Scotté F, et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2008; 12(3): 253-68.
[12]
Esmaeli B, Valero V, Ahmadi MA, Booser D. Canalicular stenosis secondary to docetaxel (taxotere): A newly recognized side effect. Ophthalmology 2001; 108(5): 994-5.
[13]
Aapro M. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: A preliminary report of the randomized phase III trial. 303 Study Group. Semin Oncol 1998; 25: 7-11.
[14]
Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005; 23(19): 4265-74.
[15]
Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol 2000; 18(12): 2354-62.
[16]
Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21(16): 3016-24.
[17]
Remenar E, Van Herpen C, Lluch JG, et al. A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable Squamous Cell Carcinoma of the Head And Neck (SCCHN). J Clin Oncol 2006; 24(18): 5516.
[18]
Chan S. Docetaxel vs. doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy. Oncology (Williston Park) 1997; 11: 19-24.
[19]
Shen G, Yu H, Bian G, et al. Genistein inhibits the proliferation of human HER2-positive cancer cells by downregulating HER2 receptor. Funct Food Health Dis 2013; 3(7): 291-9.
[20]
Vogel CL, Bellet RE. Use of docetaxel for treating cancers, US
Patent 6333348B1, 2001
[21]
Mahapatro A, Singh DK. Biodegradable nanoparticles are excellentvehicle for site directed in vivo delivery of drugs and vaccines. J Nanobiotechnology 2011; 9: 55.
[22]
Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev 2007; 59(8): 718-28.
[23]
Liversidge G, Jenkins S, Liversidge E. . Nanoparticulate formulations
of docetaxel and analogues thereof. US Patent
20060188566A1, 2006
[24]
Parijat P, Harish D. Recent patents on polymeric nanoparticles for cancer therapy. Recent Pat Nanotechnol 2018; 12(2): 155-69.
[25]
Labhasetwar V, Song C, Levy RJ. Nanoparticle drug delivery system for restenosis. Adv Drug Deliv Rev 1997; 24(1): 63-85.
[26]
Li H, Zhang Q, Sun X. XU Y, Huang W, Li A. Method for synthesizing
poly(butylene adipate-co-terephthalate). US Patent
9896539B2, 2018
[27]
Khemani K, Andersen PJ, Hodson SK, Schmidt H. . Biodegradable
polymer films and sheets suitable for use as laminate coatings as
well as wraps and other packaging materials. US Patent
6573340B1, 2003.
[28]
Youli X, Jun J, Yuyu L. PBAT (polybutyrate adipate terephthalate)
Fully-biodegradable film composition and preparation method
thereof. Chinese Patent 107189365A, 2017
[29]
Varshosaz J, Riahi S, Ghassami E, Jahanian-Najafabadi A. Transferrin-targeted poly(butylene adipate)/terephthalate nanoparticles for targeted delivery of 5-fluorouracil in HT29 colorectal cancer cell line. J Bioact Compat Polym 2017; 32(5): 503-27.
[30]
Bodor N. Redox drug delivery systems for targeting drugs to the brain. Ann N Y Acad Sci 1987; 507: 289-306.
[31]
Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: Successes, limitations and hopes for the future. Br J Pharmacol 2009; 157(2): 220-33.
[32]
O’Sullivan CK. Aptasensors - the future of biosensing. Anal Bioanal Chem 2002; 372(1): 44-8.
[33]
Mills JK, Needham D. Targeted drug delivery. J Expert Opin Ther Pat 1999; 9: 1499-513.
[34]
Meyer C, Hahn U, Rentmeister A. Cell-specific aptamers as emerging therapeutics. J Nucleic Acids 2011; 2011: 904750.
[35]
Mairal T, Özalp VC, Sánchez PL, Mir M, Katakis I, O’Sullivan CK. Aptamers: Molecular tools for analytical applications. Anal Bioanal Chem 2008; 390: 989-1007.
[36]
Murphy MB, Fuller ST, Richardson PM, Doyle SA. An improved method for the in vitro evolution of aptamers and applications in protein detection and purification. Nucleic Acids Res 2003; 31(18): e110.
[37]
Varshosaz J, Ghassami E, Noorbakhsh A, et al. Poly (butylene adipate-co-butylene terephthalate) nanoparticles prepared by electrospraying technique for docetaxel delivery in ovarian cancer induced mice. Drug Dev Ind Pharm 2018; 44(6): 1012-22.
[38]
Rutkowski S, Si T, Gai M, Frueh J, He Q. Hydrodynamic electrospray ionization jetting of calcium alginate particles: Effect of spray-mode, spraying distance and concentration. RSC Advances 2018; 8: 24243.
[39]
Collery P, Mohsen A, Kermagoret A, et al. Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer. Invest New Drugs 2015; 33(4): 848-60.
[40]
Taymouri S, Varshosaz V, Hassanzadeh F, et al. Pharmacokinetics, organ toxicity and antitumor activity of docetaxel loaded in folate targeted cholesterol based micelles. Curr Drug Deliv 2016; 13(4): 545-56.
[41]
Cardiff RD, Miller CH, Munn RJ. Manual hematoxylin and eosin stainy of mouse tissues section. Cold Spring Harb Protoc 2014; 2014(6): 655-8.
[42]
Bruey JM, Maher A. Cancer diagnosis using ki-67. US Patent
20100120080A1, 2010
[43]
Cervin C, Tinzl M, Johnsson M, et al. Properties and effects of a novel liquid crystal nanoparticle formulation of docetaxel in a prostate cancer mouse model. Eur J Pharm Sci 2010; 41(2): 369-75.
[44]
Feng SX, Guan Q, Chen T, et al. In vitro activities of 3-hydroxy-1,5,6-trimethoxy-2-methyl-9,10-anthraquinone against non-small cell lung carcinoma. Arch Pharm Res 2012; 35: 1251-8.
[45]
Ernsting MJ, Tang WL, MacCallum NW, et al. Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models. Biomaterials 2012; 33(5): 1445-54.
[46]
Miki Y, Yoshimoto K, Isomura A. Methods and kits for predicting the side effects of docetaxel therapyJapanese Patent 5015547B2,
2012
[47]
O’Connell KE, Mikkola AM, Stepanek AM, et al. Practical murine hematopathology: A comparative review and implications for research. Comp Med 2015; 65(2): 96-113.
[48]
Cataldi M, Vigliotti C, Mosca T, et al. Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes. Int J Mol Sci 2017; 18(6): E1249.
[49]
Frank GU. Nanoparticle delivery system and components thereof.
US Patent 20140005379A1, 2014
[50]
Gokhale PC, Radhakrishnan B, Husain SR, et al. An improved method of encapsulation of doxorubicin in liposomes: Pharmacological, toxicological and therapeutic evaluation. Br J Cancer 1996; 74(1): 43-8.
[51]
Zhao L, Wei YM, Zhong XD, et al. PK and tissue distribution of docetaxel in rabbits after i.v. administration of liposomal and injectable formulations. J Pharm Biomed Anal 2009; 49(4): 989-96.
[52]
He W, Frueh J, Wu Z, He Q. Leucocyte membrane-coated janus microcapsules for enhanced photothermal cancer treatment. Langmuir 2016; 32: 3637.
[53]
Gai M, Frueh J, Kudryavtseva VL, Yashchenok AM, Sukhorukov GB. Polylactic acid sealed polyelectrolyte multilayer microchambers for entrapment of salts and small hydrophilic molecules precipitates. Appl Mater Interfaces 2017; 9: 16536.
[54]
Li W, Gai M, Rutkowski S, et al. Automated device for layer-by-layer coating of dispersed superparamagnetic nanoparticle templates. Colloid J 2018; 80: 648-59.
67
8